GHRP-6 Research: The Hexapeptide That Led to the Ghrelin Receptor

What is GHRP-6?

What is GHRP-6? It is a synthetic hexapeptide — six residues, sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, with a C-terminal amide. The name is literal: growth-hormone-releasing peptide, the sixth in a numbered series. Two of its six residues are D-amino acids, which is the usual synthetic strategy for making a short peptide resistant to the proteases that would otherwise clear it quickly.

Pharmacologically it is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the receptor now known as the ghrelin receptor. That places it in a different family from the GHRH analogues sermorelin, CJC-1295 and tesamorelin, which act at the GHRH receptor. Same downstream hormone, different door. Everything below is a description of chemistry, receptor pharmacology and published research models.

Discovery and origin in the literature

A peptide with no known hormone (1984)

Bowers, Momany, Reynolds and Hong reported GHRP-6 in Endocrinology in 1984 (PMID 6714155), describing the in-vitro and in-vivo activity of “a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” The compound came out of structure–activity work on opioid-peptide fragments, not out of a search for a GHRH mimic — which is why it bears no sequence resemblance to GHRH at all. Bowers later reviewed the whole GHRP programme in Cell Mol Life Sci (1998, PMID 9893708).

Working backwards to the receptor (1996) and the hormone (1999)

This is the part that makes GHRP-6 historically distinctive, and it is a textbook case of what pharmacologists call reverse pharmacology. Because the peptide clearly worked, and clearly did not work through the GHRH receptor, it implied an unknown receptor. Howard and colleagues found it: a receptor in pituitary and hypothalamus functioning in growth hormone release, reported in Science in 1996 (PMID 8688086). That receptor in turn implied an unknown endogenous ligand, and in 1999 Kojima and colleagues isolated it from stomach and named it ghrelin (Nature, PMID 10604470).

So the ordering is worth stating plainly, because vendor pages routinely reverse it: GHRP-6 is not a ghrelin analogue designed from ghrelin. Ghrelin was found by following GHRP-6. The class review by Müller et al. (2015, Mol Metab, PMID 26042199) traces that history and the biology that grew out of it.

Reference data

Identity facts from the public chemical record (PubChem CID 4345065) and standard catalogue data. Any field that could not be sourced is omitted rather than estimated — a registered CAS number is not published in the PubChem record for this compound, so no CAS row appears below.

An analytical note that follows from the sequence: two tryptophan residues and a phenylalanine make this a strongly UV-absorbing peptide at 280 nm, which is convenient for chromatographic detection. Tryptophan is also oxidation-sensitive, so oxidised species are among the impurities a reversed-phase method is expected to resolve. Molecule and analytical facts only — no reconstitution volume, concentration or route is given or implied.

Mechanisms researchers have examined

The GHRP-6 mechanism literature centres on GHS-R1a and on the pathways that receptor touches. Each point is what studies characterised in model systems:

• GHS-R1a agonism — GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a, a Gq-coupled G-protein-coupled receptor expressed in pituitary and hypothalamus (Howard et al., 1996). Activation is described as signalling through phospholipase C and intracellular calcium mobilisation.
• Dual central and pituitary sites — the 1996 receptor paper localised expression to both pituitary and hypothalamus, and the class literature describes secretagogue action at both levels rather than at the somatotroph alone.
• Interaction with the GHRH pathway — Bowers et al. (1990, J Clin Endocrinol Metab, PMID 2108187) reported that GHRP stimulated growth hormone release in normal men and acted synergistically with GHRH. This is reported as a measured pharmacological interaction between two receptor systems in a study setting; it is not a suggestion to combine anything.
• Non-selectivity at the pituitary — Molica et al. (2010, Pituitary, PMID 20602173) measured ACTH and cortisol alongside growth hormone after GHRP-6, ghrelin and GHRH in a defined patient population. The corticotroph axis responding to a growth-hormone secretagogue is a characterised property of this compound, described here neutrally.
• GH-independent effects on adiposity — Lall et al. (2001, Biochem Biophys Res Commun, PMID 11162489) examined stimulation of adiposity by growth-hormone secretagogues in a design intended to separate it from growth hormone itself, reporting the effect was GH-independent in that model.

Research findings by area

Appetite and body weight in animal models

This is where GHRP-6 diverges most clearly from the rest of its receptor family, and it is the honest reason to treat it as a distinct compound rather than a synonym. The ghrelin receptor is an appetite receptor as well as a secretagogue receptor, and GHRP-6 engages that side of it. Lall et al. (2001) reported GH-independent stimulation of adiposity by secretagogues of this class. Granado et al. (2010, Endocrinology, PMID 20219977) examined weight gain and fat-mass accrual after GHRP-6 in rodents and found the outcome depended on the animals’ insulin and glucose status — a conditional result rather than a uniform one.

Both are rodent studies, and both are reported here as what the investigators measured in animals. Findings in rodent models cannot establish outcomes in people, and this page draws no such conclusion. It notes them because pages that present GHRP-6 as a clean growth-hormone tool are omitting a characterised, published property of the molecule.

Endocrine response in humans

The human record is older and narrower than the animal record. Bowers et al. (1990) measured growth-hormone release in normal men. Molica et al. (2010) measured GH, ACTH and cortisol responses in a hyperthyroid patient population before and after treatment, using GHRP-6 as a pharmacological probe of pituitary responsiveness. That framing — GHRP-6 as an investigative tool for characterising the axis — describes most of its human literature accurately.

Research models and evidence status

Summarised without spin: GHRP-6 has a substantial and genuinely important mechanistic literature and a thin clinical one. It earned its place in pharmacology as the probe that opened the ghrelin system, and reviews such as Müller et al. (2015) treat it that way. What it does not have is a development programme. There is no registered indication, no phase-3 trial record, and no approved product anywhere containing GHRP-6.

What is not established

No controlled human trial establishes an effect of GHRP-6 on body composition, recovery, injury healing, sleep or ageing. The adiposity and feeding results are rodent findings, obtained in specific metabolic states and reported as conditional by the authors themselves. The ACTH and cortisol data mean the compound is not a selective growth-hormone tool, and the selective alternative within the same receptor family is a separate molecule — ipamorelin, whose 1998 characterisation explicitly contrasted it with GHRP-6. Long-term safety data in healthy people do not exist. Where a compound’s reputation rests on mechanism rather than on outcomes, saying so is the accurate summary.

On anti-doping status, reported as fact and not as a use case: growth-hormone secretagogues, including the GHRP family, appear under section S2 of the World Anti-Doping Agency Prohibited List and are prohibited at all times, in and out of competition.

GHRP-6 among the ghrelin-receptor agonists

Four peptides and one non-peptide in this catalogue act at GHS-R1a, and the honest differences between them are selectivity and off-target activity rather than potency rankings:

• GHRP-6 — the original, and the least selective: characterised ACTH/cortisol response and a documented rodent appetite and adiposity literature.
• GHRP-2 — a later, more potent analogue that reached formal use as a diagnostic agent for testing pituitary reserve.
• Hexarelin — GHRP-6 plus a single methyl group on the position-2 tryptophan, with a separate CD36-mediated cardiac literature and documented desensitisation on sustained exposure.
• Ipamorelin — developed and described as the selective member of the family; its own page covers that characterisation, which is not restated here.
• MK-677 — not a peptide at all, but an orally active small molecule at the same receptor.

Receptor-family context only; nothing here is a protocol, a stack, a ranking or a recommendation.

How to verify this compound yourself

A six-residue peptide is verified by two orthogonal analytical methods, both reported on the per-batch Certificate of Analysis:

• HPLC purity — reversed-phase chromatography separates the target from synthesis-related impurities and reports purity as a percentage of the chromatogram. For GHRP-6 the impurities that matter analytically include oxidised tryptophan species and — critically — the closely related family members, since hexarelin differs from GHRP-6 by a single methyl group.
• Mass-spec identity — the measured mass is checked against the expected ≈ 873 Da. This is the check that catches substitution: hexarelin sits 14 Da higher, GHRP-2 about 55 Da lower, and a mass spectrum distinguishes them where a purity percentage alone cannot.
• Endotoxin and sterility — where tested, separate quality attributes reported in EU/mg or as a sterility result, independent of chemical purity.

See how to read a COA for what each line on a certificate means, how to verify peptide purity for how the two methods fit together, and the self-serve verify tool to check the exact batch on a vial in hand.

Research-grade sourcing and verification

For laboratory research use only. GHRP-6 is not held in stock; it is listed as available to order in the sourcing catalogue, with a typical lead time of two to three weeks and a quote on request. Material supplied ships with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Given how little separates the members of this peptide family by mass, that lot-level identity confirmation is the whole point rather than a formality. Sourcing and identity-assurance framing only.

Frequently asked questions

Literature cited

1. Bowers CY, Momany FA, Reynolds GA, Hong A. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984;114(5):1537–1545. PMID 6714155. pubmed.ncbi.nlm.nih.gov/6714155.
2. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. “Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.” J Clin Endocrinol Metab. 1990;70(4):975–982. PMID 2108187. pubmed.ncbi.nlm.nih.gov/2108187.
3. Howard AD, Feighner SD, Cully DF, et al. “A receptor in pituitary and hypothalamus that functions in growth hormone release.” Science. 1996;273(5277):974–977. PMID 8688086. pubmed.ncbi.nlm.nih.gov/8688086.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” Nature. 1999;402(6762):656–660. PMID 10604470. pubmed.ncbi.nlm.nih.gov/10604470.
5. Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cell Mol Life Sci. 1998;54(12):1316–1329. PMID 9893708. pubmed.ncbi.nlm.nih.gov/9893708.
6. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. “Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.” Biochem Biophys Res Commun. 2001;280(1):132–138. PMID 11162489. pubmed.ncbi.nlm.nih.gov/11162489.
7. Granado M, García-Cáceres C, Frago LM, Argente J, Chowen JA. “The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass accrual depend on the insulin/glucose status.” Endocrinology. 2010;151(5):2008–2018. PMID 20219977. pubmed.ncbi.nlm.nih.gov/20219977.
8. Molica P, Nascif SO, Correa-Silva SR, et al. “Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.” Pituitary. 2010;13(4):315–323. PMID 20602173. pubmed.ncbi.nlm.nih.gov/20602173.
9. Müller TD, Nogueiras R, Andermann ML, et al. “Ghrelin.” Mol Metab. 2015;4(6):437–460. PMID 26042199. pubmed.ncbi.nlm.nih.gov/26042199.
10. National Center for Biotechnology Information. “PubChem Compound Summary for CID 4345065, GHRP-6.” pubchem.ncbi.nlm.nih.gov/compound/4345065 (formula, mass).
11. World Anti-Doping Agency. “The Prohibited List” — section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org/en/prohibited-list.